{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:11:14Z","timestamp":1782738674593,"version":"3.54.5"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","award":["PCC-156736"],"award-info":[{"award-number":["PCC-156736"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institute for Health Research","doi-asserted-by":"crossref","award":["PJT-156124"],"award-info":[{"award-number":["PJT-156124"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Cancer Research Society and Ovarian Cancer Canada","award":["21123"],"award-info":[{"award-number":["21123"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Familial ovarian cancer (OC) cases not harbouring pathogenic variants in either of the\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      OC-predisposing genes, which function in homologous recombination (HR) of DNA, could involve pathogenic variants in other DNA repair pathway genes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Whole exome sequencing was used to identify rare variants in HR genes in a\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      pathogenic variant negative OC family of French Canadian (FC) ancestry, a population exhibiting genetic drift. OC cases and cancer-free individuals from FC and non-FC populations were investigated for carrier frequency of\n                      <jats:italic>FANCI<\/jats:italic>\n                      c.1813C&gt;T; p.L605F, the top-ranking candidate. Gene and protein expression were investigated in cancer cell lines and tissue microarrays, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In FC subjects, c.1813C&gt;T was more common in familial (7.1%, 3\/42) than sporadic (1.6%, 7\/439) OC cases (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.048). Carriers were detected in 2.5% (74\/2950) of cancer-free females though female\/male carriers were more likely to have a first-degree relative with OC (121\/5249, 2.3%; Spearman correlation = 0.037;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.011), suggesting a role in risk. Many of the cancer-free females had host factors known to reduce risk to OC which could influence cancer risk in this population. There was an increased carrier frequency of\n                      <jats:italic>FANCI<\/jats:italic>\n                      c.1813C&gt;T in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      pathogenic variant negative OC families, when including the discovery family, compared to cancer-free females (3\/23, 13%; OR = 5.8; 95%CI = 1.7\u201319;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.005). In non-FC subjects, 10 candidate\n                      <jats:italic>FANCI<\/jats:italic>\n                      variants were identified in 4.1% (21\/516) of Australian OC cases negative for pathogenic variants in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      , including 10 carriers of\n                      <jats:italic>FANCI<\/jats:italic>\n                      c.1813C&gt;T. Candidate variants were significantly more common in familial OC than in sporadic OC (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04). Localization of FANCD2, part of the FANCI-FANCD2 (ID2) binding complex in the Fanconi anaemia (FA) pathway, to sites of induced DNA damage was severely impeded in cells expressing the p.L605F isoform. This isoform was expressed at a reduced level, destabilized by DNA damaging agent treatment in both HeLa and OC cell lines, and exhibited sensitivity to cisplatin but not to a poly (ADP-ribose) polymerase inhibitor. By tissue microarray analyses, FANCI protein was consistently expressed in fallopian tube epithelial cells and only expressed at low-to-moderate levels in 88% (83\/94) of OC samples.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      This is the first study to describe candidate OC variants in\n                      <jats:italic>FANCI<\/jats:italic>\n                      , a member of the ID2 complex of the FA DNA repair pathway. Our data suggest that pathogenic\n                      <jats:italic>FANCI<\/jats:italic>\n                      variants may modify OC risk in cancer families.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-021-00998-5","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T12:03:29Z","timestamp":1638533009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene"],"prefix":"10.1186","volume":"13","author":[{"given":"Caitlin T.","family":"Fierheller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Guitton-Sert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wejdan M.","family":"Alenezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timoth\u00e9e","family":"Revil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen K.","family":"Oros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuandi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bedard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna L.","family":"Arcand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Serruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Behl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliane","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Fewings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak N.","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Nadaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Bruce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Foulkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaki","family":"El Haffaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Mes-Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Majewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor J.","family":"Pugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Tischkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian G.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia M. T.","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannis","family":"Ragoussis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Masson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia N.","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"issue":"1","key":"998_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Ca Cancer J Clin. 2019;69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551.","journal-title":"Ca Cancer J Clin."},{"issue":"2","key":"998_CR2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJM200007133430201","volume":"343","author":"P Lichtenstein","year":"2000","unstructured":"Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78\u201385.","journal-title":"N Engl J Med."},{"issue":"2","key":"998_CR3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molonc.2009.02.004","volume":"3","author":"JF Lynch","year":"2009","unstructured":"Lynch JF, Butts M, Snyder C, Bewtra C, Lynch J, Godwin AK, et al. Hereditary ovarian cancer: molecular genetics, pathology, management, and heterogeneity. Mol Oncol. 2009;3(2):97\u2013137.","journal-title":"Mol Oncol."},{"issue":"5","key":"998_CR4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1471-0528.1998.tb10148.x","volume":"105","author":"JF Stratton","year":"1998","unstructured":"Stratton JF, Pharoah P, Smith SK, Easton D, Ponder B. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 1998;105(5):493\u20139.","journal-title":"Br J Obstet Gynaecol."},{"issue":"23","key":"998_CR5","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K, Mooij TM, Jervis S, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402\u201316.","journal-title":"JAMA."},{"key":"998_CR6","doi-asserted-by":"publisher","unstructured":"Peres LC, Cushing-haugen KL, Ko M, Harris HR, Berchuck A, Rossing MA, et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst. 2019;111(1):60\u201368, 1, DOI: https:\/\/doi.org\/10.1093\/jnci\/djy071.","DOI":"10.1093\/jnci\/djy071"},{"issue":"5","key":"998_CR7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","volume":"16","author":"R Vang","year":"2009","unstructured":"Vang R, Shih LM, Kurman RJ. Ovarian low-grade and high grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267\u201382.","journal-title":"Adv Anat Pathol."},{"issue":"1","key":"998_CR8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","volume":"315","author":"LA Mucci","year":"2016","unstructured":"Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of cancer among twins in nordic countries. JAMA. 2016;315(1):68\u201376. https:\/\/doi.org\/10.1001\/jama.2015.17703.","journal-title":"JAMA."},{"issue":"15","key":"998_CR9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"APM Finch","year":"2014","unstructured":"Finch APM, Lubinski J, M\u00f8ller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547\u201354.","journal-title":"J Clin Oncol."},{"issue":"2","key":"998_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.296.2.185","volume":"296","author":"A Finch","year":"2006","unstructured":"Finch A, Beiner M, Lubinkski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185\u201392.","journal-title":"JAMA."},{"issue":"15","key":"998_CR11","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong PC, Yap TA, Boss DS, Carden CP, Mergui-roelvink M, Gourley C, et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512\u20139.","journal-title":"J Clin Oncol."},{"key":"998_CR12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","volume":"376","author":"MW Audeh","year":"2010","unstructured":"Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-mcguinn KM, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet Oncol. 2010;376:245\u201351.","journal-title":"Lancet Oncol."},{"key":"998_CR13","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2 , multicentre , open-label , non-randomised study. Lancet Oncol. 2011;12:852\u201361.","journal-title":"Lancet Oncol."},{"issue":"3","key":"998_CR14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol. 2015;33(3):244\u201350.","journal-title":"J Clin Oncol."},{"issue":"9","key":"998_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-lauraine","year":"2017","unstructured":"Pujade-lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2.","journal-title":"Lancet Oncol."},{"key":"998_CR16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852\u201361.","journal-title":"Lancet Oncol."},{"issue":"3","key":"998_CR17","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1371\/journal.pone.0000268","volume":"2","author":"H Song","year":"2007","unstructured":"Song H, Ramus SJ, Kjaer SK, Hogdall E, Dicioccio RA, Whittemore AS, et al. Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer. PLoS One. 2007;2(3):e268.","journal-title":"PLoS One."},{"issue":"11","key":"998_CR18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.955","volume":"43","author":"T Rafnar","year":"2011","unstructured":"Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104\u20137.","journal-title":"Nat Genet."},{"issue":"5","key":"998_CR19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","volume":"42","author":"A Meindl","year":"2010","unstructured":"Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410\u20134.","journal-title":"Nat Genet."},{"key":"998_CR20","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10549-010-1095-5","volume":"124","author":"Y Zheng","year":"2010","unstructured":"Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat. 2010;124:857\u201361.","journal-title":"Breast Cancer Res Treat."},{"issue":"17","key":"998_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1056\/NEJM197210262871705","volume":"287","author":"CM Bagley","year":"1972","unstructured":"Bagley CM, Young RC, Canellos GP, DeVita VT. Treatment of ovarian carcinoma: possibilities for progress. N Engl J Med. 1972 Oct 26;287(17):856\u201362. https:\/\/doi.org\/10.1056\/NEJM197210262871705.","journal-title":"N Engl J Med."},{"issue":"12","key":"998_CR22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/carcin\/bgq210","volume":"31","author":"K Somyajit","year":"2010","unstructured":"Somyajit K, Subramanya S, Nagaraju G. RAD51C: A novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis. 2010;31(12):2031\u20138.","journal-title":"Carcinogenesis."},{"issue":"9","key":"998_CR23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/ng.893","volume":"43","author":"C Loveday","year":"2011","unstructured":"Loveday C, Turnbull C, Ramsay E, Hughes D, Ruark E, Frankum JR, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879\u201382. https:\/\/doi.org\/10.1038\/ng.893.","journal-title":"Nat Genet."},{"issue":"12","key":"998_CR24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1093\/jnci\/djaa030","volume":"112","author":"X Yang","year":"2020","unstructured":"Yang X, Song H, Leslie G, Engel C, Hahnen E, Auber B, et al. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst. 2020;112(12):1242\u201350.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"998_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev.genom.2.1.69","volume":"2","author":"CR Scriver","year":"2001","unstructured":"Scriver CR. Human genetics: Lessons from Quebec populations. Annu Rev Genomics Hum Genet. 2001;2(1):69\u2013101. https:\/\/doi.org\/10.1146\/annurev.genom.2.1.69.","journal-title":"Annu Rev Genomics Hum Genet."},{"key":"998_CR26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1399-0004.2005.00497.x","volume":"68","author":"A-M Laberge","year":"2005","unstructured":"Laberge A-M, Michaud J, Richter A, Lemyre E, Lambert M, Brais B. Population history and its impact on medical genetics in Quebec. Clin Genet. 2005;68:287\u2013301.","journal-title":"Clin Genet."},{"key":"998_CR27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00439-010-0945-x","volume":"129","author":"M-H Roy-Gagnon","year":"2011","unstructured":"Roy-Gagnon M-H, Moreau C, Bherer C, St-onge P, Labuda D, Sinnett D, et al. Genomic and genealogical investigation of the French Canadian founder population structure. Hum Genet. 2011;129:521\u201331.","journal-title":"Hum Genet."},{"issue":"3","key":"998_CR28","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/ajpa.21424","volume":"144","author":"C Bherer","year":"2011","unstructured":"Bherer C, Labuda D, Roy-Gagnon M-H, Houde L, Tremblay M, Vezina H. Admixed ancestry and stratification of Quebec regional populations. Am J Phys Anthropol. 2011;144(3):432\u201341.","journal-title":"Am J Phys Anthropol."},{"key":"998_CR29","doi-asserted-by":"crossref","unstructured":"Fierheller CT, Alenezi WM, Tonin PN. The genetic analyses of French Canadians of Quebec facilitate the characterization of new cancer predisposing genes implicated in hereditary breast and\/or ovarian cancer syndrome families. Cancers (Basel). 2021;13(14):3406.","DOI":"10.3390\/cancers13143406"},{"key":"998_CR30","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ijc.20406","volume":"112","author":"KK Oros","year":"2004","unstructured":"Oros KK, Ghadirian P, Greenwood CMT, Perret C, Shen Z, Paredes Y, et al. Significant proportion of breast and\/or ovarian cancer families of French Canadian descent harbor 1 of 5 BRCA1 and BRCA2 mutations. Int J Cancer. 2004;112:411\u20139.","journal-title":"Int J Cancer."},{"issue":"12","key":"998_CR31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007752","volume":"14","author":"MS Cline","year":"2018","unstructured":"Cline MS, Liao RG, Parsons MT, Paten B, Alquaddoomi F, Antoniou A, et al. BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 2018;14(12):e1007752.","journal-title":"PLoS Genet."},{"key":"998_CR32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2350-14-5","volume":"14","author":"M Tischkowitz","year":"2013","unstructured":"Tischkowitz M, Sabbaghian N, Hamel N, Pouchet C, Foulkes WD, Mes-Masson A-M, et al. Contribution of the PALB2 c.2323C>T [p. Q775X] Founder mutation in well-defined breast and\/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent. BMC Med Genet. 2013;14:5.","journal-title":"BMC Med Genet"},{"issue":"16","key":"998_CR33","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1158\/0008-5472.CAN-17-0190","volume":"77","author":"B Rivera","year":"2017","unstructured":"Rivera B, Di Iorio M, Frankum J, Nadaf J, Fahiminiya S, Arcand SL, et al. Functionally null RAD51D missense mutation associates strongly with ovarian carcinoma. Cancer Res. 2017;77(16):4517\u201329. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0190.","journal-title":"Cancer Res."},{"issue":"11","key":"998_CR34","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nsmb.1504","volume":"15","author":"M Ishiai","year":"2008","unstructured":"Ishiai M, Kitao H, Smogorzewska A, Tomida J, Kinomura A, Uchida E, et al. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol. 2008;15(11):1138\u201346.","journal-title":"Nat Struct Mol Biol."},{"issue":"4","key":"998_CR35","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1073\/pnas.0407796102","volume":"102","author":"K Nakanishi","year":"2005","unstructured":"Nakanishi K, Yang Y, Pierce AJ, Taniguchi T, Digweed M, Andrea ADD, et al. Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. PNAS. 2005;102(4):1110\u20135. https:\/\/doi.org\/10.1073\/pnas.0407796102.","journal-title":"PNAS."},{"issue":"6","key":"998_CR36","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nsmb1252","volume":"14","author":"AE Sims","year":"2007","unstructured":"Sims AE, Spiteri E, Sims RJ, Arita AG, Lach FP, Landers T, et al. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol. 2007;14(6):564\u20137.","journal-title":"Nat Struct Mol Biol."},{"issue":"2","key":"998_CR37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cell.2007.03.009","volume":"129","author":"A Smogorzewska","year":"2007","unstructured":"Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER III, Hurov KE, Luo J, et al. Identification of the Fanconi anemia (FANC) I protein, a monoubiquitinated FANCD2 paralog required for crosslink repair. Cell. 2007;129(2):289\u2013301.","journal-title":"Cell."},{"key":"998_CR38","first-page":"211","volume":"29","author":"JC Dorsman","year":"2007","unstructured":"Dorsman JC, Levitus M, Rockx D, Rooimans MA, Oostra AB, Haitjema A, et al. Identification of the Fanconi anemia complementation group I gene. FANCI. Cell Oncol. 2007;29:211\u20138.","journal-title":"FANCI. Cell Oncol."},{"key":"998_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-015-0124-8","volume":"8","author":"MH Belanger","year":"2015","unstructured":"Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson A-M, et al. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population. J Ovarian Res. 2015;8:1.","journal-title":"J Ovarian Res."},{"key":"998_CR40","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1086\/302099","volume":"63","author":"PN Tonin","year":"1998","unstructured":"Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, et al. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998;63:1341\u201351.","journal-title":"Am J Hum Genet."},{"issue":"5","key":"998_CR41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1034\/j.1399-0004.1999.550504.x","volume":"55","author":"PN Tonin","year":"1999","unstructured":"Tonin PN, Mes-Masson A-M, Narod SA, Ghadirian P, Provencher D. Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history. Clin Genet. 1999 May;55(5):318\u201324.","journal-title":"Clin Genet."},{"key":"998_CR42","doi-asserted-by":"crossref","first-page":"6491","DOI":"10.1038\/s41598-020-63100-w","volume":"10","author":"S Behl","year":"2020","unstructured":"Behl S, Hamel N, de Ladurantaye M, Lepage S, Lapointe R, Mes-Masson A-M, et al. Founder BRCA1\/BRCA2\/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls. Sci Rep. 2020;10:6491.","journal-title":"Sci Rep"},{"key":"998_CR43","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1093\/ije\/dys160","volume":"42","author":"P Awadalla","year":"2013","unstructured":"Awadalla P, Boileau C, Payette Y, Idaghdour Y, Goulet J, Knoppers B, et al. Cohort profile of the CARTaGENE study: Quebec\u2019s population-based biobank for public health and personalized genomics. Int J Epidemiol. 2013;42:1285\u201399.","journal-title":"Int J Epidemiol."},{"issue":"5","key":"998_CR44","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/ng.3826","volume":"49","author":"CM Phelan","year":"2017","unstructured":"Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49(5):680\u201391.","journal-title":"Nat Genet."},{"issue":"4","key":"998_CR45","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/ng.2563","volume":"45","author":"K Michailidou","year":"2013","unstructured":"Michailidou K, Hall P, Gonzalez-neira A, Ghoussaini M, Milne RL, Schmidt MK, et al. Large-scale genotyping identified 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353\u201361.","journal-title":"Nat Genet."},{"issue":"4","key":"998_CR46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ng.3242","volume":"47","author":"K Michailidou","year":"2015","unstructured":"Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush M, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):373\u201380.","journal-title":"Nat Genet."},{"key":"998_CR47","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41467-020-15461-z","volume":"11","author":"DN Subramanian","year":"2020","unstructured":"Subramanian DN, Zethoven M, Mcinerny S, Morgan JA, Rowley SM, Lee JEA, et al. Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes. Nat Commun. 2020;11:1640.","journal-title":"Nat Commun"},{"issue":"4","key":"998_CR48","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41436-018-0277-0","volume":"21","author":"SM Rowley","year":"2018","unstructured":"Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, et al. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. Genet Med. 2018;21(4):913\u201322. https:\/\/doi.org\/10.1038\/s41436-018-0277-0.","journal-title":"Genet Med."},{"issue":"11","key":"998_CR49","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1200\/JCO.2002.05.121","volume":"20","author":"BDA Berry","year":"2002","unstructured":"Berry BDA, Iversen ES, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1\/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol. 2002;20(11):2701\u201312.","journal-title":"J Clin Oncol."},{"key":"998_CR50","doi-asserted-by":"crossref","unstructured":"Goldman MJ, Craft B, Hastie M, Repe\u010dka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nature biotechnology. 2020;38:675\u20138.","DOI":"10.1038\/s41587-020-0546-8"},{"issue":"10","key":"998_CR51","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/nprot.2015.105","volume":"10","author":"H Yang","year":"2015","unstructured":"Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 2015;10(10):1556\u201366. https:\/\/doi.org\/10.1038\/nprot.2015.105.","journal-title":"Nat Protoc."},{"key":"998_CR52","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/nar\/gks539","volume":"40","author":"N Sim","year":"2012","unstructured":"Sim N, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40:452\u20137.","journal-title":"Nucleic Acids Res."},{"issue":"7571","key":"998_CR53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"A Auton","year":"2015","unstructured":"1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68\u201374.","journal-title":"Nature."},{"key":"998_CR54","unstructured":"Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP) [Internet]. Seattle, WA. [cited 2014 Feb 21]. Available from: http:\/\/evs.gs.washington.edu\/EVS\/"},{"issue":"1","key":"998_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson JT, Thorvaldsd\u00f3ttir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative Genomics Viewer. Nat Biotechnol. 2011;29(1):24\u20136. https:\/\/doi.org\/10.1038\/nbt.1754.","journal-title":"Nat Biotechnol."},{"key":"998_CR56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285\u201391.","journal-title":"Nature."},{"key":"998_CR57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniak AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas resource. Cell Rep. 2018;23:239\u201354.","journal-title":"Cell Rep."},{"issue":"3","key":"998_CR58","doi-asserted-by":"crossref","first-page":"e59722","DOI":"10.1371\/journal.pone.0059722","volume":"8","author":"A Fedick","year":"2013","unstructured":"Fedick A, Su J, Jalas C, Northrop L, Devkota B, Ekstein J, et al. High-throughput carrier screening using TaqMan allelic discrimination. PLoS One. 2013;8(3):e59722.","journal-title":"PLoS One."},{"issue":"10","key":"998_CR59","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1038\/ng.3643","volume":"48","author":"S Mccarthy","year":"2016","unstructured":"Mccarthy S, Das S, Kretzschmar W, Delaneau O, Wood AR, Teumer A, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;48(10):1279\u201383. https:\/\/doi.org\/10.1038\/ng.3643.","journal-title":"Nat Genet."},{"issue":"11","key":"998_CR60","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3679","volume":"48","author":"P Loh","year":"2016","unstructured":"Loh P, Danecek P, Palamara PF, Fuchsberger C, Reshef YA, Finucane HK, et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat Genet. 2016;48(11):1443\u20138.","journal-title":"Nat Genet."},{"issue":"9","key":"998_CR61","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/bioinformatics\/btu014","volume":"30","author":"R Durbin","year":"2014","unstructured":"Durbin R. Efficient haplotype matching and storage using the positional Burrows-Wheeler transform (PBWT). Bioinformatics. 2014;30(9):1266\u201372.","journal-title":"Bioinformatics."},{"key":"998_CR62","doi-asserted-by":"publisher","unstructured":"Ghosh R, Oak N, Plon SE. Evaluation of in silico algorithms for use with ACMG\/AMP clinical variant interpretation guidelines. Genome Biol. 2017 28;18(255), 1, DOI: https:\/\/doi.org\/10.1186\/s13059-017-1353-5.","DOI":"10.1186\/s13059-017-1353-5"},{"issue":"12","key":"998_CR63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1001025","volume":"6","author":"EV Davydov","year":"2010","unstructured":"Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A. Identifying a high fraction of the human genome to be under selective constraint using GERP ++. PLoS Comput Biol. 2010;6(12):e1001025.","journal-title":"PLoS Comput Biol."},{"issue":"1","key":"998_CR64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1101\/gr.097857.109","volume":"20","author":"KS Pollard","year":"2010","unstructured":"Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 2010;20(1):110\u201321.","journal-title":"Genome Res."},{"issue":"8","key":"998_CR65","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1101\/gr.3715005","volume":"15","author":"A Siepel","year":"2005","unstructured":"Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005;15(8):1034\u201350. https:\/\/doi.org\/10.1101\/gr.3715005.","journal-title":"Genome Res."},{"issue":"12","key":"998_CR66","doi-asserted-by":"crossref","first-page":"i54","DOI":"10.1093\/bioinformatics\/btp190","volume":"25","author":"M Garber","year":"2009","unstructured":"Garber M, Guttman M, Clamp M, Zody MC, Friedman N, Xie X. Identifying novel constrained elements by exploiting biased substitution patterns. Bioinformatics. 2009;25(12):i54\u201362.","journal-title":"Bioinformatics."},{"issue":"D1","key":"998_CR67","doi-asserted-by":"publisher","first-page":"D886","DOI":"10.1093\/nar\/gky1016","volume":"47","author":"P Rentzsch","year":"2019","unstructured":"Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886\u201394. https:\/\/doi.org\/10.1093\/nar\/gky1016.","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"998_CR68","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ajhg.2011.03.004","volume":"88","author":"A Gonz\u00e1lez-P\u00e9rez","year":"2011","unstructured":"Gonz\u00e1lez-P\u00e9rez A, L\u00f3pez-Bigas N. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score. Condel. Am J Hum Genet. 2011;88(4):440\u20139.","journal-title":"Condel. Am J Hum Genet."},{"issue":"2","key":"998_CR69","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ng.3477","volume":"48","author":"I Ionita-Laza","year":"2016","unstructured":"Ionita-Laza I, McCallum K, Xu B, Buxbaum JD. A spectral approach integrating functional genomic annotations for coding and noncoding variants. Nat Genet. 2016;48(2):214\u201320.","journal-title":"Nat Genet."},{"issue":"8","key":"998_CR70","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/hmg\/ddu733","volume":"24","author":"C Dong","year":"2015","unstructured":"Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet. 2015;24(8):2125\u201337.","journal-title":"Hum Mol Genet."},{"issue":"1","key":"998_CR71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/humu.22911","volume":"37","author":"C Douville","year":"2016","unstructured":"Douville C, Masica DL, Stenson PD, Cooper DN, Gygax DM, Kim R, et al. Assessing the pathogenicity of insertion and deletion variants with the variant effect scoring tool (VEST-Indel). Hum Mutat. 2016;37(1):28\u201335.","journal-title":"Hum Mutat."},{"issue":"4","key":"998_CR72","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","volume":"99","author":"NM Ioannidis","year":"2016","unstructured":"Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99(4):877\u201385. https:\/\/doi.org\/10.1016\/j.ajhg.2016.08.016.","journal-title":"Am J Hum Genet."},{"issue":"13","key":"998_CR73","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/bioinformatics\/bty960","volume":"35","author":"J Shamsani","year":"2019","unstructured":"Shamsani J, Kazakoff SH, Armean IM, McLaren W, Parsons MT, Thompson BA, et al. A plugin for the Ensembl Variant Effect Predictor that uses MaxEntScan to predict variant spliceogenicity. Bioinformatics. 2019;35(13):2315\u20137.","journal-title":"Bioinformatics."},{"issue":"22","key":"998_CR74","doi-asserted-by":"crossref","first-page":"13534","DOI":"10.1093\/nar\/gku1206","volume":"42","author":"X Jian","year":"2014","unstructured":"Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in the human genome. Nucleic Acids Res. 2014;42(22):13534\u201344.","journal-title":"Nucleic Acids Res."},{"key":"998_CR75","doi-asserted-by":"publisher","unstructured":"Mclaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17(122) https:\/\/doi.org\/10.1186\/s13059-016-0974-4.","DOI":"10.1186\/s13059-016-0974-4"},{"issue":"2","key":"998_CR76","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"K-L Huang","year":"2018","unstructured":"Huang K-L, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic germline variants in 10,389 adult cancers. Cell. 2018;173(2):355\u2013370.e14.","journal-title":"Cell"},{"key":"998_CR77","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:1062\u20137.","journal-title":"Nucleic Acids Res."},{"key":"998_CR78","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.celrep.2017.02.028","volume":"18","author":"M Medrano","year":"2017","unstructured":"Medrano M, Communal L, Brown KR, Iwanicki M, Normand J, Paterson J, et al. Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer. Cell Rep. 2017;18:2343\u201358.","journal-title":"Cell Rep."},{"key":"998_CR79","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10689-007-9152-x","volume":"6","author":"PN Tonin","year":"2007","unstructured":"Tonin PN, Maugard CM, Perret C, Mes-Masson AM, Provencher DM. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. Fam Cancer. 2007;6:491\u20137.","journal-title":"Fam Cancer."},{"key":"998_CR80","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1136\/jmg.2003.017996","volume":"41","author":"DGR Evans","year":"2004","unstructured":"Evans DGR, Eccles DM, Rahman N, Young K, Bulman M, Amir E, et al. A new scoring system for the chances of identifying a BRCA1\/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004;41:474\u201380.","journal-title":"J Med Genet."},{"key":"998_CR81","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/jmedgenet-2017-104584","volume":"54","author":"DG Evans","year":"2017","unstructured":"Evans DG, Harkness EF, Plaskocinska I, Wallace AJ, Clancy T, Woodward ER, et al. Pathology update to the Manchester Scoring System based on testing in over 4000 families. J Med Genet. 2017;54:674\u201381.","journal-title":"J Med Genet."},{"issue":"4","key":"998_CR82","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1399-0004.2006.00673.x","volume":"70","author":"KK Oros","year":"2006","unstructured":"Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson A-M, et al. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and\/or ovarian cancer families of French Canadian descent. Clin Genet. 2006;70(4):320\u20139. https:\/\/doi.org\/10.1111\/j.1399-0004.2006.00673.x.","journal-title":"Clin Genet."},{"issue":"6","key":"998_CR83","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.cell.2017.05.010","volume":"169","author":"SLW Tan","year":"2017","unstructured":"Tan SLW, Chadha S, Liu Y, Gabasova E, Perera D, Ahmed K, et al. A class of environmental and endogenous toxins induces BRCA2 haploinsufficiency and genome instability. Cell [Internet]. 2017;169(6):1105\u20131118.e15 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28575672.","journal-title":"Cell [Internet]"},{"issue":"1","key":"998_CR84","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1182\/blood-2012-07-441212","volume":"121","author":"Y Kim","year":"2013","unstructured":"Kim Y, Spitz GS, Veturi U, Lach FP, Auerbach AD, Smogorzewska A. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood. 2013;121(1):54\u201364. https:\/\/doi.org\/10.1182\/blood-2012-07-441212.","journal-title":"Blood."},{"issue":"3","key":"998_CR85","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/1097-0215(20010520)95:3<189::AID-IJC1032>3.0.CO;2-N","volume":"95","author":"PN Tonin","year":"2001","unstructured":"Tonin PN, Perret C, Lambert JA, Paradis AJ, Kantemiroff T, Beno\u00eet MH, et al. Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. Int J Cancer. 2001;95(3):189\u201393. https:\/\/doi.org\/10.1002\/1097-0215(20010520)95:3<189::AID-IJC1032>3.0.CO;2-N.","journal-title":"Int J Cancer."},{"issue":"1","key":"998_CR86","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12881-015-0169-y","volume":"16","author":"SL Arcand","year":"2015","unstructured":"Arcand SL, Akbari MR, Provencher D, Foulkes WD, Narod SA, Tonin PN. Germline TP53 mutational spectrum in French Canadians with breast cancer. BMC Med Genet. 2015;16(1):24. https:\/\/doi.org\/10.1186\/s12881-015-0169-y.","journal-title":"BMC Med Genet."},{"issue":"1","key":"998_CR87","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/1471-2407-8-239","volume":"8","author":"DJ Novak","year":"2008","unstructured":"Novak DJ, Chen LQ, Ghadirian P, Hamel N, Zhang P, Rossiny V, et al. Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women. BMC Cancer. 2008;8(1):239. https:\/\/doi.org\/10.1186\/1471-2407-8-239.","journal-title":"BMC Cancer."},{"issue":"16","key":"998_CR88","doi-asserted-by":"publisher","first-page":"6788","DOI":"10.1073\/pnas.0701724104","volume":"104","author":"M Tischkowitz","year":"2007","unstructured":"Tischkowitz M, Xia B, Sabbaghian N, Reis-filho JS, Hamel N, Li G, et al. Analysis of PALB2\/FANCN-associated breast cancer families. PNAS. 2007;104(16):6788\u201393. https:\/\/doi.org\/10.1073\/pnas.0701724104.","journal-title":"PNAS."},{"issue":"1","key":"998_CR89","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10549-011-1796-4","volume":"131","author":"S Cote","year":"2012","unstructured":"Cote S, Arcand SL, Royer R, Nolet S, Mes-Masson A, Ghadirian P, et al. The BRCA2 c.9004G>A (E2002K) [corrected] variant is likely pathogenic and recurs in breast and\/or ovarian cancer families of French Canadian descent. Breast Cancer Res Treat. 2012 Jan;131(1):333\u201340. https:\/\/doi.org\/10.1007\/s10549-011-1796-4.","journal-title":"Breast Cancer Res Treat."},{"issue":"8","key":"998_CR90","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1038\/bjc.2012.87","volume":"106","author":"DJ Osher","year":"2012","unstructured":"Osher DJ, De Leeneer K, Michils G, Hamel N, Tomiak E, Poppe B, et al. Mutation analysis of RAD51D in non-BRCA1\/2 ovarian and breast cancer families. Br J Cancer. 2012;106(8):1460\u20133. https:\/\/doi.org\/10.1038\/bjc.2012.87.","journal-title":"Br J Cancer."},{"issue":"2","key":"998_CR91","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0002-9378(98)70372-2","volume":"179","author":"B Godard","year":"1998","unstructured":"Godard B, Foulkes WD, Provencher D, Brunet JS, Tonin PN, Mes-Masson AM, et al. Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol. 1998;179(2):403\u201310. https:\/\/doi.org\/10.1016\/S0002-9378(98)70372-2.","journal-title":"Am J Obstet Gynecol."},{"key":"998_CR92","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-2350-7-23","volume":"7","author":"KK Oros","year":"2006","unstructured":"Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Foulkes WD, et al. Haplotype analysis suggest common founder in carriers of recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and\/ovarian cancer families. BMC Med Genet. 2006;7:23.","journal-title":"BMC Med Genet."},{"issue":"3","key":"998_CR93","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10549-007-9608-6","volume":"108","author":"SL Arcand","year":"2008","unstructured":"Arcand SL, Maugard CM, Ghadirian P, Robidoux A, Perret C, Zhang P, et al. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat. 2008;108(3):399\u2013408.","journal-title":"Breast Cancer Res Treat."},{"key":"998_CR94","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2407-8-96","volume":"8","author":"L Cavallone","year":"2008","unstructured":"Cavallone L, Arcand SL, Maugard C, Ghadirian P, Provencher D, Tonin PN. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer. 2008;8:96.","journal-title":"BMC Cancer."},{"key":"998_CR95","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s10689-010-9372-3","volume":"9","author":"L Cavallone","year":"2010","unstructured":"Cavallone L, Arcand SL, Maugard CM, Nolet S, Gaboury LA, Mes-Masson AM, et al. Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Fam Cancer. 2010;9:507\u201317.","journal-title":"Fam Cancer."},{"issue":"7809","key":"998_CR96","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alf\u00f6ldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434\u201343. https:\/\/doi.org\/10.1038\/s41586-020-2308-7.","journal-title":"Nature."},{"key":"998_CR97","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","volume":"2","author":"UA Matulonis","year":"2016","unstructured":"Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Prim. 2016;2:16061.","journal-title":"Nat Rev Dis Prim."},{"issue":"1","key":"998_CR98","doi-asserted-by":"crossref","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","volume":"14","author":"BM Reid","year":"2017","unstructured":"Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a summary review. Cancer Biol Med. 2017;14(1):9\u201332.","journal-title":"Cancer Biol Med."},{"key":"998_CR99","unstructured":"PDQ Cancer Genetics Editorial Board. Genetics of breast and gynecologic cancers (PDQ\u00ae): health professional version. PDQ Cancer Information Summaries. Bethesda, MD: National Cancer Institute (US);"},{"issue":"2","key":"998_CR100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","volume":"31","author":"DW Kindelberger","year":"2007","unstructured":"Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161\u20139.","journal-title":"Am J Surg Pathol."},{"issue":"25","key":"998_CR101","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.2007.12.2622","volume":"25","author":"MJ Callahan","year":"2007","unstructured":"Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25(25):3985\u201390.","journal-title":"J Clin Oncol."},{"issue":"25","key":"998_CR102","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2008.16.4814","volume":"26","author":"JW Carlson","year":"2008","unstructured":"Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26(25):4160\u20135.","journal-title":"J Clin Oncol."},{"key":"998_CR103","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","volume":"100","author":"A Finch","year":"2006","unstructured":"Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58\u201364.","journal-title":"Gynecol Oncol."},{"key":"998_CR104","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-galy","year":"2017","unstructured":"Labidi-galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8:1093.","journal-title":"Nat Commun"},{"key":"998_CR105","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1006\/gyno.2002.6779","volume":"87","author":"K Leeper","year":"2002","unstructured":"Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52\u20136.","journal-title":"Gynecol Oncol."},{"issue":"1","key":"998_CR106","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2005.04.109","volume":"23","author":"CB Powell","year":"2005","unstructured":"Powell CB, Kenley E, Chen L, Crawford B, Mclennan J, Zaloudek C, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23(1):127\u201332.","journal-title":"J Clin Oncol."},{"issue":"23","key":"998_CR107","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1158\/1078-0432.CCR-17-0638","volume":"23","author":"D Hao","year":"2017","unstructured":"Hao D, Li J, Jia S, Meng Y, Zhang C, Wang L, et al. Integrated analysis reveals tubal- and ovarian-originated serous ovarian cancer and predicts differential therapeutic responses. Clin Cancer Res. 2017;23(23):7400\u201311.","journal-title":"Clin Cancer Res."},{"issue":"1","key":"998_CR108","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13073-020-00786-7","volume":"12","author":"P Lo Riso","year":"2020","unstructured":"Lo Riso P, Villa CE, Gasparoni G, Vingiani A, Luongo R, Manfredi A, et al. A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. Genome Med. 2020;12(1):94.","journal-title":"Genome Med."},{"issue":"1","key":"998_CR109","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","volume":"10","author":"S Zhang","year":"2019","unstructured":"Zhang S, Dolgalev I, Zhang T, Ran H, Levine DA, Neel BG. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nat Commun. 2019;10(1):5367. https:\/\/doi.org\/10.1038\/s41467-019-13116-2.","journal-title":"Nat Commun."},{"key":"998_CR110","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/bcr1828","volume":"9","author":"WD Foulkes","year":"2007","unstructured":"Foulkes WD, Ghadirian P, Akbari MR, Hamel N, Giroux S, Sabbaghian N, et al. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women. Breast Cancer Res. 2007;9:R83.","journal-title":"Breast Cancer Res."},{"issue":"6","key":"998_CR111","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/cge.12526","volume":"87","author":"E Castellsagu\u00e9","year":"2015","unstructured":"Castellsagu\u00e9 E, Liu J, Volenik A, Giroux S, Gagn\u00e9 R, Maranda B, et al. Characterization of a novel founder MSH6 mutation causing Lynch syndrome in the French Canadian population. Clin Genet. 2015;87(6):536\u201342. https:\/\/doi.org\/10.1111\/cge.12526.","journal-title":"Clin Genet."},{"issue":"2-3","key":"998_CR112","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00439-005-1297-9","volume":"117","author":"H Vezina","year":"2005","unstructured":"Vezina H, Durocher F, Dumont M, Houde L, Szabo C, Tranchant M, et al. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast\/ovarian cancer families. Hum Genet. 2005;117(2-3):119\u201332. https:\/\/doi.org\/10.1007\/s00439-005-1297-9.","journal-title":"Hum Genet."},{"issue":"2","key":"998_CR113","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000053364","volume":"52","author":"AP Manning","year":"2001","unstructured":"Manning AP, Abelovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, et al. Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian Yemenite Jewish hereditary breast cancer families. Hum Hered. 2001;52(2):116\u201320. https:\/\/doi.org\/10.1159\/000053364.","journal-title":"Hum Hered."},{"issue":"9","key":"998_CR114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045484","volume":"7","author":"PM Wojnarowicz","year":"2012","unstructured":"Wojnarowicz PM, Oros KK, Quinn MCJ, Arcand SL, Gambaro K, Madore J, et al. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLoS One. 2012;7(9):e45484.","journal-title":"PLoS One."},{"issue":"7353","key":"998_CR115","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609\u201315.","journal-title":"Nature."},{"key":"998_CR116","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-017-00388-9","volume":"8","author":"KN Maxwell","year":"2017","unstructured":"Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8:319.","journal-title":"Nat Commun."},{"key":"998_CR117","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1086\/341943","volume":"71","author":"P Vahteristo","year":"2002","unstructured":"Vahteristo P, Bartkova J, Eerola H, Syrja K, Ojala S, Kilpivaara O, et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet. 2002;71:432\u20138.","journal-title":"Am J Hum Genet."},{"issue":"1","key":"998_CR118","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","volume":"104","author":"N Mavaddat","year":"2019","unstructured":"Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet. 2019;104(1):21\u201334.","journal-title":"Am J Hum Genet."},{"issue":"5","key":"998_CR119","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1136\/jmedgenet-2019-106739","volume":"58","author":"H Song","year":"2021","unstructured":"Song H, Dicks EM, Tyrer J, Intermaggio M, Chenevix-Trench G, Bowtell DD, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer. J Med Genet. 2021;58(5):305\u201313.","journal-title":"J Med Genet."},{"issue":"7","key":"998_CR120","doi-asserted-by":"crossref","first-page":"8310","DOI":"10.18632\/oncotarget.7027","volume":"7","author":"P-H Lin","year":"2016","unstructured":"Lin P-H, Kuo W-H, Huang A-C, Lu Y-S, Lin C-H, Kuo S-H, et al. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Oncotarget. 2016;7(7):8310\u201320.","journal-title":"Oncotarget."},{"issue":"8","key":"998_CR121","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/ijc.31921","volume":"144","author":"E Girard","year":"2018","unstructured":"Girard E, Eon-Marchais S, Olaso R, Renault A, Dondon M, Barjhoux L, et al. Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing. Int J Cancer. 2018;144(8):1962\u201374.","journal-title":"Int J Cancer."},{"issue":"11","key":"998_CR122","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1093\/carcin\/bgp218","volume":"30","author":"MJ Garcia","year":"2009","unstructured":"Garcia MJ, Fernandez V, Osorio A, Barroso A, Fernandez F, Urioste M, et al. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi anemia genes, only FANCD1\/BRCA2 plays a major role in high-risk breast cancer predisposition. Carcinogenesis. 2009;30(11):1898\u2013902. https:\/\/doi.org\/10.1093\/carcin\/bgp218.","journal-title":"Carcinogenesis."},{"key":"998_CR123","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10549-015-3545-6","volume":"153","author":"MS Ellingson","year":"2015","unstructured":"Ellingson MS, Hart SN, Kalari KR, Suman V, Schahl KA, Dockter TJ, et al. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat. 2015;153:435\u201343.","journal-title":"Breast Cancer Res Treat."},{"issue":"4","key":"998_CR124","volume":"10","author":"X Yang","year":"2015","unstructured":"Yang X, Wu J, Lu J, Liu G, Di G, Chen C. Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next- generation sequencing. PLoS One. 2015;10(4):e0125571.","journal-title":"PLoS One."},{"key":"998_CR125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/cge.12447","volume":"88","author":"T Mantere","year":"2015","unstructured":"Mantere T, Haanp\u00e4\u00e4 M, Hanenberg H, Schleutker J, Kallioniemi A, Kahkonen M, et al. Finnish Fanconi anemia mutations and hereditary predisposition to breast and prostate cancer. Clin Genet. 2015;88:68\u201373.","journal-title":"Clin Genet."},{"issue":"12","key":"998_CR126","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00432-018-2763-9","volume":"144","author":"S Bonache","year":"2018","unstructured":"Bonache S, Esteban I, Moles-Fern\u00e1ndez A, Ten\u00e9s A, Duran-Lozano L, Montalban G, et al. Multigene panel testing beyond BRCA1\/2 in breast\/ovarian cancer Spanish families and clinical actionability of findings. J Cancer Res Clin Oncol. 2018;144(12):2495\u2013513.","journal-title":"J Cancer Res Clin Oncol."},{"issue":"29","key":"998_CR127","doi-asserted-by":"crossref","first-page":"47064","DOI":"10.18632\/oncotarget.16791","volume":"8","author":"G Tedaldi","year":"2017","unstructured":"Tedaldi G, Tebaldi M, Zampiga V, Danesi R, Arcangeli V, Ravegnani M, et al. Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. Oncotarget. 2017;8(29):47064\u201375.","journal-title":"Oncotarget."},{"issue":"4","key":"998_CR128","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007355","volume":"14","author":"P Paulo","year":"2018","unstructured":"Paulo P, Maia S, Pinto C, Pinto P, Monteiro A, Peixoto A, et al. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset\/familial prostate cancer. PLoS Genet. 2018;14(4):e1007355.","journal-title":"PLoS Genet."},{"issue":"2","key":"998_CR129","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.eururo.2018.09.040","volume":"76","author":"PI Velho","year":"2018","unstructured":"Velho PI, Qazi F, Hassan S, Carducci MA, Denmeade SR, Markowski MC, et al. Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects. Eur Urol. 2018;76(2):170\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2018.09.040.","journal-title":"Eur Urol."},{"issue":"1","key":"998_CR130","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1038\/s41598-017-10333-x","volume":"7","author":"SH Chan","year":"2017","unstructured":"Chan SH, Lim WK, Diana N, Ishak B, Li S, Goh WL, et al. Germline mutations in cancer predisposition genes are frequent in sporadic sarcomas. Sci Rep. 2017;7(1):10660.","journal-title":"Sci Rep."},{"key":"998_CR131","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","volume":"405","author":"M Betti","year":"2017","unstructured":"Betti M, Casalone E, Ferrante D, Aspesi A, Morleo G, Biasi A, et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett. 2017;405:38\u201345. https:\/\/doi.org\/10.1016\/j.canlet.2017.06.028.","journal-title":"Cancer Lett."},{"key":"998_CR132","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-018-0090-7","volume":"8","author":"KZY Maung","year":"2018","unstructured":"Maung KZY, Leo PJ, Bassal M, Casolari DA, Gray JX, Bray SC, et al. Rare variants in Fanconi anemia genes are enriched in acute myeloid leukemia. Blood Cancer J. 2018;8:50.","journal-title":"Blood Cancer J"},{"issue":"20","key":"998_CR133","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/cncr.30802","volume":"123","author":"SC Chandrasekharappa","year":"2017","unstructured":"Chandrasekharappa SC, Chinn SB, Donovan FX, Chowdhury NI, Kamat A, Adeyemo AA, et al. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50. Cancer. 2017;123(20):3943\u201354.","journal-title":"Cancer."},{"key":"998_CR134","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3389\/fonc.2019.00673","volume":"9","author":"G Zhunussova","year":"2019","unstructured":"Zhunussova G, Afonin G, Abdikerim S, Jumanov A, Perfilyeva A, Kaidarova D, et al. Mutation spectrum of cancer-associated genes in patients with early onset of colorectal cancer. Front Oncol. 2019;9:673.","journal-title":"Front Oncol"},{"issue":"10","key":"998_CR135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1005563","volume":"11","author":"M Castella","year":"2015","unstructured":"Castella M, Jacquemont C, Thompson EL, Yeo JE, Cheung RS, Huang JW, et al. FANCI regulates recruitment of the FA core complex at sites of DNA damage independently of FANCD2. PLoS Genet. 2015;11(10):e1005563.","journal-title":"PLoS Genet."},{"key":"998_CR136","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature."},{"issue":"3","key":"998_CR137","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41436-019-0682-z","volume":"22","author":"T Wiltshire","year":"2019","unstructured":"Wiltshire T, Ducy M, Foo TK, Hu C, Lee KY, Nagaraj AB, et al. Functional characterization of 84 PALB2 variants of uncertain significance. Genet Med. 2019;22(3):622\u201332. https:\/\/doi.org\/10.1038\/s41436-019-0682-z.","journal-title":"Genet Med."},{"issue":"20","key":"998_CR138","doi-asserted-by":"crossref","first-page":"10662","DOI":"10.1093\/nar\/gkz780","volume":"47","author":"A Rodrigue","year":"2019","unstructured":"Rodrigue A, Margaillan G, Gomes TT, Coulombe Y, Montalban G, Carvalho S, et al. A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor. Nucleic Acids Res. 2019;47(20):10662\u201377.","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"998_CR139","doi-asserted-by":"publisher","first-page":"46","DOI":"10.14304\/surya.jpr.v4n5.1","volume":"4","author":"N Chatterjee","year":"2016","unstructured":"Chatterjee N, Lin Y, Wilson JH. Fanconi anemia pathway regulates convergent trancription-induced cell death at trinucleotide repeats in human cells. Postdoc J. 2016;4(5):46\u201354. https:\/\/doi.org\/10.14304\/surya.jpr.v4n5.1.","journal-title":"Postdoc J."},{"issue":"2","key":"998_CR140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molcel.2015.02.031","volume":"58","author":"Y Chen","year":"2016","unstructured":"Chen Y, Jones MJK, Yin Y, Crist SB, Colnaghi L, Sims RJ III, et al. ATR-mediated phosphorylation of FANCI regulates dormant origin firing in response to replication stress. Mol Cell. 2016;58(2):323\u201338.","journal-title":"Mol Cell."},{"issue":"22","key":"998_CR141","doi-asserted-by":"crossref","first-page":"10758","DOI":"10.1093\/nar\/gkw876","volume":"44","author":"K Sato","year":"2016","unstructured":"Sato K, Shimomuki M, Katsuki Y, Takahashi D, Kobayashi W, Ishiai M, et al. FANCI-FANCD2 stabilizes the RAD51-DNA complex by binding RAD51 and protects the 5\u2019-DNA end. Nucleic Acids Res. 2016;44(22):10758\u201371.","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"998_CR142","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1080\/15384101.2016.1158375","volume":"15","author":"X Zhang","year":"2016","unstructured":"Zhang X, Lu X, Akhter S, Georgescu M, Legerski RJ. FANCI is a negative regulator of Akt activation. Cell Cycle. 2016;15(8):1134\u201343. https:\/\/doi.org\/10.1080\/15384101.2016.1158375.","journal-title":"Cell Cycle."},{"issue":"7","key":"998_CR143","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1073\/pnas.1811557116","volume":"116","author":"SB Sondalle","year":"2019","unstructured":"Sondalle SB, Longerich S, Ogawa LM, Sung P, Baserga SJ. Fanconi anemia protein FANCI functions in ribosome biogenesis. PNAS. 2019;116(7):2561\u201370.","journal-title":"PNAS."},{"key":"998_CR144","unstructured":"Mehta PA, Tolar J. Fanconi Anemia. In: Pagon R, Adam M, Ardinger H, editors. GeneReviews(\u00ae) [Internet] [Internet]. Seattle (WA): University of Washington, Seattle; 2002. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9590114"},{"issue":"2","key":"998_CR145","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ajmg.a.37461","volume":"170A","author":"SA Savage","year":"2015","unstructured":"Savage SA, Ballew BJ, Giri N, Dceg NCI, Genomics C, Chandrasekharappa SC, et al. Novel FANCI mutations in Fanconi anemia with VACTERL Association. Am J Med Genet Part A. 2015;170A(2):386\u201391. https:\/\/doi.org\/10.1002\/ajmg.a.37461.","journal-title":"Am J Med Genet Part A."},{"issue":"3","key":"998_CR146","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3324\/haematol.2017.176131","volume":"103","author":"R Bottega","year":"2018","unstructured":"Bottega R, Nicchia E, Cappelli E, Ravera S, De Rocco D, Faleschini M, et al. Hypomorphic FANCA mutations correlate with mild mitochondrial and clinical phenotype in Fanconi anemia. Haematologica. 2018;103(3):417\u201326. https:\/\/doi.org\/10.3324\/haematol.2017.176131.","journal-title":"Haematologica."},{"issue":"9","key":"998_CR147","doi-asserted-by":"crossref","first-page":"e863","DOI":"10.1002\/mgg3.863","volume":"7","author":"K Keupp","year":"2019","unstructured":"Keupp K, Hampp S, H\u00fcbbel A, Maringa M, Kostezka S, Rhiem K, et al. Biallelic germline BRCA1 mutations in a patient with early onset breast cancer, mild Fanconi anemia-like phenotype, and no chromosome fragility. Mol Genet Genomic Med. 2019;7(9):e863.","journal-title":"Mol Genet Genomic Med"},{"issue":"3","key":"998_CR148","doi-asserted-by":"crossref","first-page":"e1005945","DOI":"10.1371\/journal.pgen.1005945","volume":"12","author":"PJ Byrd","year":"2016","unstructured":"Byrd PJ, Stewart GS, Smith A, Eaton C, Taylor AJ, Guy C, et al. A hypomorphic PALB2 allele gives rise to an unusual form of FA-N associated with lymphoid tumour development. PLoS Genet. 2016;12(3):e1005945.","journal-title":"PLoS Genet"},{"key":"998_CR149","doi-asserted-by":"publisher","unstructured":"Caburet S, Heddar A, Dardillac E, Creux H, Lambert M, Messiaen S, et al. Homozygous hypomorphic BRCA2 variant in primary ovarian insufficiency without cancer or Fanconi anaemia trait. J Med Genet. 2020. https:\/\/doi.org\/10.1136\/jmedgenet-2019-106672.","DOI":"10.1136\/jmedgenet-2019-106672"},{"key":"998_CR150","unstructured":"Lohmann DR, Gallie BL. Retinoblastoma. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. Seattle (WA); 1993."},{"issue":"22","key":"998_CR151","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1182\/blood-2012-12-474585","volume":"121","author":"SC Chandrasekharappa","year":"2013","unstructured":"Chandrasekharappa SC, Lach FP, Kimble DC, Kamat A, Teer JK, Donovan FX, et al. Massively parallel sequencing , aCGH , and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia. Blood. 2013;121(22):e138\u201348.","journal-title":"Blood"},{"issue":"14","key":"998_CR152","doi-asserted-by":"publisher","first-page":"7532","DOI":"10.1093\/nar\/gkz514","volume":"47","author":"EL Dubois","year":"2019","unstructured":"Dubois EL, Guitton-Sert L, B\u00e9liveau M, Parmar K, Chagraoui J, Vignard J, et al. A Fanci knockout mouse model reveals common and distinct functions for FANCI and FANCD2. Nucleic Acids Res. 2019;47(14):7532\u201347. https:\/\/doi.org\/10.1093\/nar\/gkz514.","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"998_CR153","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38(7):674\u201385.","journal-title":"J Clin Oncol."},{"issue":"33","key":"998_CR154","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","volume":"31","author":"PG Moorman","year":"2013","unstructured":"Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Urrutia RP, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188\u201398.","journal-title":"J Clin Oncol."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-021-00998-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-021-00998-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-021-00998-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T12:04:40Z","timestamp":1638533080000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-021-00998-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":154,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["998"],"URL":"https:\/\/doi.org\/10.1186\/s13073-021-00998-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.05.04.20090407","asserted-by":"object"}]},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"2 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project has received approval from The McGill University Health Centre (MUHC) REB (MP-37-2019-4783 and 2017-2722). All participants provided informed consent and the research conformed to the principles of the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Participants whose pedigree data is presented in this manuscript gave consent to publish family history in pedigree or summarized format.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}